GRN 1201

Drug Profile

GRN 1201

Alternative Names: GRN-1201

Latest Information Update: 12 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GreenPeptide
  • Developer BrightPath Biotherapeutics
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Malignant melanoma

Most Recent Events

  • 01 Jul 2017 GreenPeptide is now called BrightPath Biotherapeutics
  • 26 Feb 2016 Phase-I clinical trials in Malignant melanoma in USA (Intradermal)
  • 03 Feb 2016 Preclinical trials in Malignant melanoma in USA (Intradermal) before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top